• Home
  • Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

Author List
Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yagci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K
Publication
European journal of haematology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/321215347
Publication Year
2022
PubMed ID
35871357
Publication Title
Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yagci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022 Nov; 109(5):504-512.